Published: Sept. 4, 2019, 2:16 p.m.
The National Institute for Health and Care Excellence (NICE) approved the use of a new gene therapy treatment that could slow down sight loss.
The exciting development could see NHS England patients living with a rare inherited eye disorder access the service as soon as early next year.
Charity Retina UK had been actively involved throughout the NICE decision-making process and we spoke with its CEO, Tina Houlihan to find out how the treatment could change lives.
Ms Houlihan spoke with RNIB Connect Radio’s Simon Pauley.